A New Era for Single Ventricle Science: Introducing the Translational Accelerator
September 3, 2025
Today marks a pivotal new chapter in our work and in the future of single ventricle care.
Additional Ventures has launched the Translational Accelerator, a groundbreaking program that will enable the next phase of progress in single ventricle science: moving translation-ready ideas beyond the lab and toward patients.
Across our community and beyond, researchers are generating high-potential discoveries; yet, too many stall at the edge of possibility because the ecosystem isn’t built to support what comes next.
With this launch, we’re closing the resource gaps that have long stalled translational progress in the field: gaps in funding, in mentorship, and in the strategic support needed for regulatory readiness.
The Additional Ventures Translational Accelerator was developed to help researchers bridge the “valley of death” in single ventricle science, removing early-stage roadblocks and equipping researchers with the funding and expertise needed to advance promising discoveries toward clinical reality.
The Accelerator supports two independent award streams that each target a critical area of need in translational science: therapeutics and devices.
As the first award under this Accelerator, we’ve partnered with the Consortium for Technology & Innovation in Pediatrics (CTIP) to create the AV-CTIP Device Innovation Award.
This initiative advances early-stage device concepts purpose-built for single ventricle patients across every stage of treatment. By supporting early-stage device innovators, this program seeks to fill critical gaps in care for single ventricle patients, catalyze clinical translation, and ultimately improve long term outcomes for this high-need community.
Applications for the AV-CTIP Device Innovation Award are now open.
Learn more about Additional Ventures’ vision behind the Translational Accelerator.